Grifols, S.A. (NASDAQ:GRFS – Get Free Report) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 5,530,000 shares, a decrease of 9.5% from the August 15th total of 6,110,000 shares. Based on an average daily volume of 1,740,000 shares, the days-to-cover ratio is currently 3.2 days. Approximately 2.2% of the company’s stock are sold short.
Grifols Price Performance
Shares of Grifols stock traded down $0.34 during midday trading on Tuesday, reaching $8.90. 815,654 shares of the company’s stock traded hands, compared to its average volume of 2,133,314. Grifols has a 52 week low of $5.30 and a 52 week high of $12.15. The company’s 50 day simple moving average is $8.14 and its 200 day simple moving average is $7.28. The company has a quick ratio of 0.80, a current ratio of 1.68 and a debt-to-equity ratio of 1.06.
Grifols (NASDAQ:GRFS – Get Free Report) last announced its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). The company had revenue of $1.96 billion during the quarter. Grifols had a return on equity of 1.73% and a net margin of 0.90%. Equities analysts forecast that Grifols will post 0.79 EPS for the current year.
Institutional Investors Weigh In On Grifols
About Grifols
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.
Featured Articles
- Five stocks we like better than Grifols
- Most Volatile Stocks, What Investors Need to Know
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- 3 Small Caps With Big Return Potential
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.